Hermansky-Pudlak Syndrome — Research Summary
Printed from RareWays (rareways.com.au) on 24 September 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Neutrophil Activation Signature Associated with Pulmonary Fibrosis in Hermansky—Pudlak Syndrome Type 1 2308849
Lourdes Caro-Rivera et al. — The Journal of Immunology (28 July 2026)
https://doi.org/10.1093/jimmun/vkag141.1470
- 2.
HERMANSKY–PUDLAK SYNDROME: A RARE CAUSE OF PROGRESSIVE INTERSTITIAL LUNG DISEASE IN A YOUNG ADULT
Dr. Gowtham B.1*, Dr. Monna Mohamed Jaber2, Dr. Arjunan M.3, Dr. Sundareswaran M.3 — European Journal Pharmaceutical and Medical Research (10 July 2026)
https://doi.org/10.5281/zenodo.21294304
- 3.
HERMANSKY–PUDLAK SYNDROME: A RARE CAUSE OF PROGRESSIVE INTERSTITIAL LUNG DISEASE IN A YOUNG ADULT
Dr. Gowtham B.1*, Dr. Monna Mohamed Jaber2, Dr. Arjunan M.3, Dr. Sundareswaran M.3 — European Journal Pharmaceutical and Medical Research (10 July 2026)
https://doi.org/10.5281/zenodo.21294305
- 4.
Assessment of patient-reported symptoms in Hermansky-Pudlak syndrome.
Zuo Mei Xing G et al. — Molecular genetics and metabolism (1 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42150436/
- 5.
Long-read sequencing reveals SVA insertion in AP3B1 causing Hermansky-Pudlak syndrome 2.
Baba Naomi et al. — Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (1 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42432877/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Hermansky-Pudlak Syndrome
Hermansky-Pudlak syndrome is a rare inherited condition that affects pigment in the skin, hair and eyes, and causes a bleeding tendency because platelets do not work normally. Some types also lead to lung scarring or bowel inflammation. Care includes vision and skin protection, bleeding precautions around surgery and dental work, and monitoring of the lungs and bowel.
Most Recent Research
Abstract Introduction Hermansky—Pudlak Syndrome type 1 (HPS-1) is a rare lysosomal disorder in which all patients develop progressive pulmonary fibrosis. Neutrophils are increasingly recognized as drivers of epithelial injury and aberrant repair, but the systemic inflammatory signatures that distinguish fibrotic from non-fibrotic HPS remain unclear. We quantified plasma immune mediators to derive pathway-based neutrophil activation and fibrosis remodeling scores, aiming to determine whether circulating profiles reflect HPS disease phenotype and clinical severity. Methods Plasma from HPS-Fibrotic (HPS-F), HPS-Nonfibrotic (HPS-NF), Nonfibrotic Lung Disease (NFLD), and Healthy Controls (HC) was analyzed using NULISAseq™. A Neutrophil Activation Score (NAS-10) with 10 markers and a Fibrosis Remodeling Score with 8 markers for epithelial injury and profibrotic injury was computed. Group comparisons used nonparametric testing; clinical associations were assessed using Spearman correlations. Results NAS-10 was significantly higher in HPS-F compared with HPS-NF (p = 0.034) and HC (p = 0.034), indicating increased neutrophil activation in fibrotic disease. The Fibrosis Score was also significantly elevated in HPS-F relative to HC (p < 0.0001). Both indices were associated with pulmonary function, showing inverse correlations with FVC% (Fibrosis Score: r = —0.74, p = 0.046; NAS-10: r = —0.72, p = 0.037). In addition, NAS-10 correlated positively with the Fibrosis Score (r = 0.80, p = 0.014), linking neutrophil-driven inflammation with fibrotic remodeling in HPS-associated lung disease. Conclusion High-dimensional immune profiling enables the development of composite scores that discriminate fibrotic from non-fibrotic HPS and show strong associations with pulmonary function decline. Together, these findings support the use of immune signatures as tools for disease monitoring and for guiding therapeutic studies in HPS-associated pulmonary fibrosis. Funding Source Research Centers in Minority Institutions (RCMI) Center for Research Resources Grant and the Molecular and Genomics Core (#U54MD007579), PR-INBRE Developmental Research Project Program (DRPP) (#5P20GM103475-21). Graham Grant. Topic Categories Immune Mechanisms of Human Disease (HUM)
Common Questions
What is Hermansky-Pudlak Syndrome?
Hermansky-Pudlak syndrome is a rare inherited condition that affects pigment in the skin, hair and eyes, and causes a bleeding tendency because platelets do not work normally. Some types also lead to lung scarring or bowel inflammation. Care includes vision and skin protection, bleeding precautions around surgery and dental work, and monitoring of the lungs and bowel.
How many clinical trials are available for Hermansky-Pudlak Syndrome?
RareWays currently indexes 6 clinical trials for Hermansky-Pudlak Syndrome, of which 1 is actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Hermansky-Pudlak Syndrome come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Hermansky-Pudlak Syndrome.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.